Brief: Lantern Pharma’S Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation In Glioblastoma From The FDA
15/10/2024 14:09
Oct 15 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA’S INVESTIGATIONAL DRUG-CANDIDATE, LP-184,
RECEIVES FAST-TRACK DESIGNATION IN GLIOBLASTOMA FROM THE FDA
* LANTERN PHARMA INC - PHASE 1B/2A TRIAL FOR RECURRENT GBM
TO
START LATE 2024
Source text for Eikon: ID:nBw2srZjta
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments